"COLO 205人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

【細(xì)胞培養(yǎng)經(jīng)驗分享】啟蒙老師的重要性：一般進(jìn)實驗室都有師兄師姐帶著做，他們就是你做細(xì)胞的啟蒙老師。他們的操作手法、細(xì)節(jié)、理論講解就成了你操作的準(zhǔn)則，如營養(yǎng)液、細(xì)胞瓶的擺放位置、滅菌處理程序、開蓋手法、細(xì)胞吹打手法等等。要學(xué)會他們的正確操作，在第一次的時候就要重視。像養(yǎng)孩子一樣養(yǎng)細(xì)胞，細(xì)胞有時真的很脆弱，最好每天都去看看它，以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異?，F(xiàn)象，也好及時解決這些意外，避免重復(fù)實驗帶來的更大痛苦。好細(xì)胞要及時保種：細(xì)胞要分批傳代，這樣即使有一批出了問題，還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓(xùn)，有一次細(xì)胞污染了，全軍覆沒。當(dāng)時可后悔沒有保種。細(xì)胞跟人一樣，不同的細(xì)胞，培養(yǎng)特性是不一樣的。培養(yǎng)過程中要細(xì)細(xì)體會，不同細(xì)胞系使用不同的培養(yǎng)基和血清。

換液周期：每周2-3次

PIEC Cells;背景說明：髖動脈；內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-SH-SY5Y細(xì)胞、GC-1 spg細(xì)胞、WiDr-TC細(xì)胞

L 132 Cells;背景說明：胚肺；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Roswell Park Memorial Institute 8226細(xì)胞、MES-13細(xì)胞、H1694細(xì)胞

AU 565 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４—１：６傳代；每３-５天換一次液。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Det 562細(xì)胞、OCM1細(xì)胞、WC00097細(xì)胞

COLO 205人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：該細(xì)胞系是１９５７年由T.U.Sle等從患有結(jié)腸癌的７０歲男性白人的腹水中分離的。該病人在取腹水樣前已用５-尿嘧啶治療４~６周。角蛋白免疫過氧化物酶染色陽性；產(chǎn)生A、IL１０。

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

公司細(xì)胞系主要引進(jìn)ATCC、DSMZ、JCRB、KCLB、RIKEN、ECACC等細(xì)胞庫，細(xì)胞系體外培養(yǎng)，它們會成長為單層細(xì)胞，附著或緊貼在培養(yǎng)瓶上，或懸浮在體外的溶液中，細(xì)胞系復(fù)蘇周期短，公司細(xì)胞系狀態(tài)良好，飽滿，有光澤等優(yōu)點。EDTA的作用：許多人不用胰酶，只用EDTA，或者用胰酶/EDTA聯(lián)合作用。這里要明白，胰酶切割細(xì)胞外基質(zhì)的一些負(fù)責(zé)粘連和附著的蛋白，而EDTA通過螯合Ca離子，作用于整聯(lián)蛋白的活性，所以EDTA的作用更加溫和。有的人在胰酶里添加一些EDTA，或者對付特別難消化的細(xì)胞，添加多一些EDTA，就是這個道理。一般不要試圖延長消化時間(如果10min還消化不下來的話)，而應(yīng)該想其它辦法。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

COLO 205人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

T9 Cells;背景說明：膠質(zhì)瘤；Fischer ３４４;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PLA801D細(xì)胞、CWR22-R1細(xì)胞、NCIH250細(xì)胞

T-47-D Cells;背景說明：浸潤性導(dǎo)管癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BTI-TN5B1-4細(xì)胞、Panc_08_13細(xì)胞、KMST6細(xì)胞

HEK-293 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Ramos 2G6.4C10細(xì)胞、OCI-Ly19細(xì)胞、NPA'87細(xì)胞

MM1-S Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長特性：混合生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：NR8383細(xì)胞、L-M (TK-)細(xì)胞、UMRC2細(xì)胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

正確的細(xì)胞復(fù)蘇需知事項：細(xì)胞凍存HAO了，接下來要注意什么問題呢？沒錯，就是記得到時間了，拿出來復(fù)蘇。那么，細(xì)胞復(fù)蘇的過程中又有哪些該注意的事項呢？細(xì)胞活力和形態(tài)檢查的作用何在？活力檢查——千萬不要使用不健康的細(xì)胞，可能有污染(真菌、支原體等)，如果發(fā)現(xiàn)有污染毫不猶豫的丟棄!形態(tài)檢查——檢查細(xì)胞的固有形態(tài)和生長行為。凍存細(xì)胞：補充新的培養(yǎng)——在您開始凍存細(xì)胞的前一天補充新的培養(yǎng)。在細(xì)胞長至７０%單層時收獲細(xì)胞，計數(shù)活細(xì)胞數(shù)，用凍存調(diào)整細(xì)胞密度~５ x１０６  s/ml (根據(jù)不同的細(xì)胞類型調(diào)整)；凍存——用凍存洗細(xì)胞并用凍存重懸細(xì)胞，有不同類型的凍存，根據(jù)細(xì)胞類型選擇Zui合適的凍存(常用的凍存成分有)：５-１０% DMSO——注意確保DMSO不含有其他的毒性物質(zhì)；５-１５%甘油；如果細(xì)胞在無血清培養(yǎng)基內(nèi)生長，應(yīng)在５０%條件培養(yǎng)基內(nèi)(細(xì)胞在無血清培養(yǎng)基內(nèi)生長２４小時)內(nèi)凍存和復(fù)蘇。在凍存管上標(biāo)記HAO細(xì)胞類型，日期，凍存人等信息，并保證每凍存管不超過１.５ml。放入罐之前記錄凍存管的數(shù)量和位置。以Zui快的速度轉(zhuǎn)移凍存管知罐內(nèi)，因此，此步驟ZuiHAO使用干冰，或者把凍存管浸入裝有的小盒內(nèi)。此外還要注意，在凍存管上沒有足夠的空間記錄細(xì)胞的詳細(xì)信息，做HAO記錄是非常非常重要的！還有一個Zui重要的，一定要在異地的罐內(nèi)保存同樣的一份細(xì)胞，以免其中的一個罐出現(xiàn)問題！細(xì)胞正確的復(fù)蘇方式和正確的凍存方式同樣重要，熟記以下要點：當(dāng)從罐內(nèi)取出細(xì)胞時，有可能會出現(xiàn)凍存管破裂的情況，使用保護(hù)面罩和防護(hù)服十分必要；其實，細(xì)胞復(fù)蘇只是一個簡單的實驗，不過這其中卻不可避免有一些需要注意的細(xì)節(jié)，不然，也不一定會盡如人意。例如說，人身健康方面：一定要記得做HAO防凍工作，戴上護(hù)目鏡；盡量降低DMSO對細(xì)胞的損傷等等。

Rat Basophilic Leukemia-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Sp2/O-Ag14細(xì)胞、PG-LH7細(xì)胞、CAL-27細(xì)胞

T 98 G Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：按１：３傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：FHs74Int細(xì)胞、MLA144細(xì)胞、MPC-83細(xì)胞

B16-F0 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs737T細(xì)胞、AK細(xì)胞、HOEC細(xì)胞

CFPAC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１０傳代；２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：NCIH524細(xì)胞、HEL9217細(xì)胞、DMS-153細(xì)胞

L-5178-Y-R Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WPE-int細(xì)胞、SW260細(xì)胞、OUMS23細(xì)胞

NPA87-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SUM 52PE細(xì)胞、Y3細(xì)胞、HT 1376細(xì)胞

Colon-38 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：CEM/0細(xì)胞、786-0WT細(xì)胞、LTEP-s細(xì)胞

SW-1463 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：８傳代，每周換液１-２次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HO1-N-1細(xì)胞、MCF.7細(xì)胞、BEAS2B細(xì)胞

HDF-a Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-330細(xì)胞、HCC-38細(xì)胞、MILE SVEN 1細(xì)胞

NCI-H2087 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：懸浮生長，有少數(shù)細(xì)胞疏松貼壁;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SW962細(xì)胞、2B4細(xì)胞、KYSE30細(xì)胞

HOS-143B Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：５傳代；每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：混合型;相關(guān)產(chǎn)品有：DSL6A/C1細(xì)胞、SK_N_FI細(xì)胞、RCCJF細(xì)胞

ECV 304 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-MEL24細(xì)胞、NCI-H596細(xì)胞、THLE-2細(xì)胞

C 6 Cells;背景說明：膠質(zhì)細(xì)胞株C６是由Benda等用N-nitrosomethylurea誘導(dǎo)的大鼠膠質(zhì)瘤克隆，并經(jīng)過一系列的體外培養(yǎng)和動物傳代交替后建成的。 當(dāng)細(xì)胞從低密度生長到滿瓶時，S-１００產(chǎn)量增加１０倍。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：3T3-L1細(xì)胞、NT2D1細(xì)胞、Factor Dependent Continuous-Paterson 1細(xì)胞

OCILY-3 Cells;背景說明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs 888Lu細(xì)胞、Walker/LLC-WRC256細(xì)胞、P3X63 Ag8.653細(xì)胞

PLA801C Cells;背景說明：肺巨細(xì)胞癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MBT-2細(xì)胞、CCD-19Lu細(xì)胞、Experimental Mammary Tumour-6細(xì)胞

NCI-H441 Cells;背景說明：NCI-H４４１建系于１９８２年（A.F.Gazdar，etal.)。該細(xì)胞分離自一名肺腺癌患者的心包液。該細(xì)胞能在半固體瓊脂糖中形成克隆，并能表達(dá)肺泡表面活性蛋白A。該細(xì)胞在有血清培養(yǎng)基中倍增時間為５８小時，在無血清培養(yǎng)基中倍增時間為９９-１３８小時。;傳代方法：１：３傳代,２-３天傳一代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HCC-366細(xì)胞、MN 60細(xì)胞、DITNC1細(xì)胞

X63-AG 8.653 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LAN-5細(xì)胞、OVCAR433細(xì)胞、H-157細(xì)胞

A9G TG40 Cells(提供STR鑒定圖譜)

Abcam Raji DFFB KO Cells(提供STR鑒定圖譜)

BALB/3T3 clone A31 NTG2 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRR440 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHD426 Cells(提供STR鑒定圖譜)

CH-P1R2.D17 Cells(提供STR鑒定圖譜)

DA01621 Cells(提供STR鑒定圖譜)

DrRPE Cells(提供STR鑒定圖譜)

GM03811 Cells(提供STR鑒定圖譜)

KG-1a Cells;背景說明：急性髓系白血?。荒行?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HVSMC細(xì)胞、ROS17/28細(xì)胞、QG-56細(xì)胞

COLO 205人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

OVCAR10 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U 937細(xì)胞、LS-180細(xì)胞、SAOS 2細(xì)胞

T 24 Cells;背景說明：該細(xì)胞源自一位８１歲白人女性患者的膀胱移行細(xì)胞癌組織；來源于移行細(xì)胞癌病人的白血病和血漿對T２４和相關(guān)細(xì)胞株有細(xì)胞毒性；倍增時間為１９小時；含ras(H-ras)癌基因,表達(dá)腫瘤特有抗原。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MDA-MB415細(xì)胞、ECC 10細(xì)胞、SUNE1細(xì)胞

P3J Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周２-３次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：SW48細(xì)胞、P3-x63-Ag8 653細(xì)胞、CHOK1細(xì)胞

PANC-04-03 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MPC-83細(xì)胞、ADR-RES細(xì)胞、H-II-E-C3細(xì)胞

ADR-RES Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SG231細(xì)胞、B-16細(xì)胞、Hs600T細(xì)胞

6C12 [Mouse hybridoma against T.annularis PA2 inhibitor gamma A2] Cells(提供STR鑒定圖譜)

GM03570 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Onda 11細(xì)胞、NIHOVCAR3細(xì)胞、Mouse Bladder Tumor line-2細(xì)胞

IMR 90 Cells;背景說明：W.W. Nichols及其同事從一位１６周女嬰的肺中取材，建立了人二倍體成纖維細(xì)胞株IMR-９０。分裂潛能，病毒感受性和其它性質(zhì)都得到了充分研究，因而這株細(xì)胞可以作為WI-３８或其它標(biāo)準(zhǔn)人肺細(xì)胞株的替代株。有報道稱這株細(xì)胞在表現(xiàn)出衰老前可倍增５８次。;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNU-398細(xì)胞、SCLC-21H細(xì)胞、Sp2/mIL-6細(xì)胞

HGC-27 Cells;背景說明：未分化胃癌，能分泌粘液素。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：FLS細(xì)胞、H510細(xì)胞、Roswell Park Memorial Institute 7951細(xì)胞

HLF-a Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：TW01細(xì)胞、MDAMB330細(xì)胞、COLO.205細(xì)胞

578T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：ME1細(xì)胞、MES 23.5細(xì)胞、HT 29細(xì)胞

He-La Cells;背景說明：HeLa是第一個來自人體組織經(jīng)連續(xù)培養(yǎng)獲得的非整倍體上皮樣細(xì)胞系，它由GeyGO等在１９５１年從３１歲女性黑人的宮頸癌組織建立。經(jīng)原始組織切片重新觀察，Jones等將其診斷為腺癌。已知該細(xì)胞系含有人乳頭狀瘤病毒HPV１８序列，需在２級生物安全防護(hù)臺操作。該細(xì)胞角蛋白陽性，p５３表達(dá)量較低，但表達(dá)正常水平的pRB（視網(wǎng)膜母細(xì)胞瘤抑制因子）。;傳代方法：１：３傳代，２-３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NCI-H1703細(xì)胞、J 82細(xì)胞、THP1細(xì)胞

HCT FET Cells;背景說明：結(jié)腸癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NBLAN5T細(xì)胞、MDCK supertube細(xì)胞、HO1-N-1細(xì)胞

NCIH1694 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長特性：懸浮生長;形態(tài)特性：聚團懸浮;相關(guān)產(chǎn)品有：GC1-SPG細(xì)胞、S3-HeLa細(xì)胞、Hs 636 T細(xì)胞

GM11980 Cells(提供STR鑒定圖譜)

HAP1 DMD (-) 4 Cells(提供STR鑒定圖譜)

HepG2/C3A Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SUM-102PT細(xì)胞、HUCCT1細(xì)胞、LS411細(xì)胞

SJCRH30 Cells;背景說明：肺泡橫紋肌肉瘤；骨髓轉(zhuǎn)移;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SBC-3細(xì)胞、RCC-10RGB細(xì)胞、NCI660細(xì)胞

OCIAML4 Cells;背景說明：急性髓系白血??；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NG10815細(xì)胞、A2780/Taxol細(xì)胞、3T3 clone A31細(xì)胞

HPAF2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EB-2細(xì)胞、NCI-H1373細(xì)胞、NCIH358細(xì)胞

HS940 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：Panc_02_03細(xì)胞、Anip-973細(xì)胞、A-9細(xì)胞

Eca109 Cells;背景說明：１９７３年建系，來自人食管中段鱗癌組織，小塊法原代培養(yǎng)建系。BALB/c裸鼠移植成瘤。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H283細(xì)胞、B104 [Rat neuroblastoma]細(xì)胞、H1341細(xì)胞

293T Cells;背景說明：２９３細(xì)胞株插入SV４０T-抗原的溫度敏感基因后產(chǎn)生的高轉(zhuǎn)染效率的衍生株稱為２９３T。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：CMT-64細(xì)胞、HL-60 clone15細(xì)胞、SMA560細(xì)胞

NCI-H1404 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：THP-1細(xì)胞、159PT細(xì)胞、XWLC-05細(xì)胞

HHW339 Cells(提供STR鑒定圖譜)

IOZCAS-Spex-IX Cells(提供STR鑒定圖譜)

MA139 Cells(提供STR鑒定圖譜)

ND08299 Cells(提供STR鑒定圖譜)

PG-LH7 Cells(提供STR鑒定圖譜)

TN-368-13 Cells(提供STR鑒定圖譜)

UFCVM Boa imperator kidney Cells(提供STR鑒定圖譜)

HAP1 ZBTB24 (-) 3 Cells(提供STR鑒定圖譜)

SNU-119 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HL7702細(xì)胞、IBRS2細(xì)胞、PaCa2細(xì)胞

Human Lung Microvascular Endothelial Cell line-5a Cells;背景說明：肺微血管；內(nèi)皮細(xì)胞；SV４０轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HS940細(xì)胞、S.B.細(xì)胞、Ca761細(xì)胞

DoTc2-4510 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：３傳代，每周換液２—３次;生長特性：貼壁生長　;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MS-751細(xì)胞、RPMI no. 8226細(xì)胞、SG231細(xì)胞

MADISON LUNG TA-109 Cells;背景說明：肺癌；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PK136細(xì)胞、MIA PaCa-2細(xì)胞、C666-1細(xì)胞

MA-c Cells;背景說明：星形膠質(zhì) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H69/P細(xì)胞、UMUC-3細(xì)胞、Alexander cells細(xì)胞

CEM clone 7 Cells;背景說明：急性T淋巴細(xì)胞白血?。慌?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NKM-1細(xì)胞、BTI-TN5B1-4細(xì)胞、SW-620細(xì)胞

WM 239-A Cells;背景說明：黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BCP1細(xì)胞、H-2106細(xì)胞、TE353.SK細(xì)胞

MHCC-97 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U-343細(xì)胞、LL2細(xì)胞、PTK-1細(xì)胞

Karpas 422 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WC00059細(xì)胞、NS-1細(xì)胞、TC7細(xì)胞

Mel-624 Cells;背景說明：黑色素瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CCK81細(xì)胞、OCI-Ly8細(xì)胞、KYSE-30細(xì)胞

CF Pac1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１０傳代；２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：bEND.3細(xì)胞、32D-Cl3細(xì)胞、HCC-1588細(xì)胞

CHAGOK1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：８傳代；每周換液２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Caov-3細(xì)胞、NCIH1417細(xì)胞、H322T細(xì)胞

H-1395 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；５-６天傳代一次。;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：A549-Taxol細(xì)胞、NCI-322細(xì)胞、UO-31細(xì)胞

TE3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HT 1376細(xì)胞、NCI-H1650細(xì)胞、GL-261細(xì)胞

DoHH2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：VMRCRCZ細(xì)胞、KYSE 180細(xì)胞、H-2291細(xì)胞

Sf-RVN Cells(提供STR鑒定圖譜)

HR8348 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DHL10細(xì)胞、LS174T細(xì)胞、DMS153細(xì)胞

Human Embryo Kidney-2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U-251-MG細(xì)胞、JROECL 21細(xì)胞、C-26細(xì)胞

TE-10 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NGEC細(xì)胞、SK-N-BE(2)-C細(xì)胞、SUPB-15細(xì)胞

NCIH1092 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：隨細(xì)胞的密度而增加;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RCC-JF細(xì)胞、D283細(xì)胞、SK-OV-433細(xì)胞

BI-Mel Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代，２-３天換液１次。;生長特性：混合生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：KHYG-1細(xì)胞、SkChA1細(xì)胞、SW.620細(xì)胞

RCCJF Cells;背景說明：腎透明細(xì)胞癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HSC-1細(xì)胞、UMUC1細(xì)胞、CLONE M3細(xì)胞

COLO 205人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

32Dcl3 Cells;背景說明：骨髓淋巴瘤；C３H/HeJ;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NIH3T3細(xì)胞、A 2780 CP細(xì)胞、WPMY-1細(xì)胞

H-64 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：IOSE-80細(xì)胞、RDES細(xì)胞、HPASMC細(xì)胞

H-2170 Cells;背景說明：該細(xì)胞１９８９年建系，源自一位患有肺鱗狀細(xì)胞癌的男性，該患者不吸煙;傳代方法：１：３—１：６傳代，３—５天換液１次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：WILL-2細(xì)胞、Y-79細(xì)胞、RN-c細(xì)胞

MA-104 Cells;背景說明：胚腎；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Rin-M-5F細(xì)胞、HNSC細(xì)胞、SU-DH-L5細(xì)胞

HT-55 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：BT-474細(xì)胞、COR-L88細(xì)胞、TE9細(xì)胞

HCT_116 Cells;背景說明：結(jié)腸腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RT4-D6P2T細(xì)胞、YD-15細(xì)胞、L1210細(xì)胞

HANK-1 Cells;背景說明：NK/T細(xì)胞淋巴瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EFO 27細(xì)胞、BTI-Tn5B14細(xì)胞、FUOV1細(xì)胞

UMUC1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GP293細(xì)胞、Strain KB細(xì)胞、CT26WT細(xì)胞

BayGenomics ES cell line RRR194 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHD159 Cells(提供STR鑒定圖譜)

HSDM1C1 Cells(提供STR鑒定圖譜)

PCRP-HDAC6-1A4 Cells(提供STR鑒定圖譜)

EGV-3T Cells(提供STR鑒定圖譜)

HPS2428 Cells(提供STR鑒定圖譜)

" "PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=7651727

Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M., Steele G., Summerhayes I.C.

Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.

Oncogene 11:647-652(1995)

PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)

PubMed=9294210; DOI=10.1073/pnas.94.19.10330; PMCID=PMC23362

Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.

Beta-catenin mutations in cell lines established from human colorectal cancers.

Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997)

PubMed=10051639; DOI=10.1073/pnas.96.5.2316; PMCID=PMC26781

Efstathiou J.A., Liu D., Wheeler J.M.D., Kim H.C., Beck N.E., Ilyas M., Karayiannakis A.J., Mortensen N.J., Kmiot W.A.W., Playford R.J., Pignatelli M., Bodmer W.F.

Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells.

Proc. Natl. Acad. Sci. U.S.A. 96:2316-2321(1999)

PubMed=10674020; DOI=10.1016/S0959-8049(99)00206-3

Ku J.-L., Yoon K.-A., Kim D.-Y., Park J.-G.

Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines.

Eur. J. Cancer 35:1724-1729(1999)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=10737795; DOI=10.1073/pnas.97.7.3352; PMCID=PMC16243

Rowan A.J., Lamlum H., Ilyas M., Wheeler J.M.D., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

PubMed=12584437; DOI=10.1159/000068544

Melcher R., Koehler S., Steinlein C., Schmid M., Mueller C.R., Luehrs H., Menzel T., Scheppach W., Moerk H., Scheurlen M., Koehrle J., Al-Taie O.

Spectral karyotype analysis of colon cancer cell lines of the tumor suppressor and mutator pathway.

Cytogenet. Genome Res. 98:22-28(2002)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514

Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Cancer Res. 70:5901-5911(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=23272949; DOI=10.1186/1755-8794-5-66; PMCID=PMC3543849

Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.

BMC Med. Genomics 5:66.1-66.15(2012)

PubMed=23631600; DOI=10.1021/pr400260h

Loftus N.J., Lai L., Wilkinson R.W., Odedra R., Wilson I.D., Barnes A.J.

Global metabolite profiling of human colorectal cancer xenografts in mice using HPLC-MS/MS.

J. Proteome Res. 12:2980-2986(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013

Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Cancer Res. 74:3238-3247(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25841592; DOI=10.1016/j.jprot.2015.03.019

Piersma S.R., Knol J.C., de Reus I., Labots M., Sampadi B.K., Pham T.V., Ishihama Y., Verheul H.M.W., Jimenez C.R.

Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines.

J. Proteomics 127:247-258(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25926053; DOI=10.1038/ncomms8002

Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Nat. Commun. 6:7002.1-7002.10(2015)

PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457

Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E., Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R., Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.

Clin. Cancer Res. 21:3695-3704(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=26537799; DOI=10.1074/mcp.M115.051235; PMCID=PMC4762531

Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.

N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.

Mol. Cell. Proteomics 15:124-140(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)

PubMed=28192450; DOI=10.1371/journal.pone.0171435; PMCID=PMC5305277

Fasterius E., Raso C., Kennedy S.A., Rauch N., Lundin P., Kolch W., Uhlen M., Al-Khalili Szigyarto C.

A novel RNA sequencing data analysis method for cell line authentication.

PLoS ONE 12:E0171435-E0171435(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28683746; DOI=10.1186/s12943-017-0691-y; PMCID=PMC5498998

Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Mol. Cancer 16:116.1-116.16(2017)

PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010; PMCID=PMC5583477

Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J.H., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Genomic determinants of protein abundance variation in colorectal cancer cells.

Cell Rep. 20:2201-2214(2017)

PubMed=29718670; DOI=10.1021/acs.jproteome.8b00165; PMCID=PMC6670293

Clark D.J., Hu Y.-W., Bocik W., Chen L.-J., Schnaubelt M., Roberts R.R., Shah P., Whiteley G.R., Zhang H.

Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics.

J. Proteome Res. 17:2205-2215(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)"